Vice President
Revolution Medicines
Vice President
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
As a Vice Presidentreporting to the SVP of Translational Research in Biology,the individual will collaborate with colleagues in Research and Development to serve as the scientific and organizational leader of the Cancer Pharmacology function and help shape the translational research strategy supporting Revolution Medicines' discovery and development portfolio. The cancer pharmacology effort is accountable for delivering mechanistic, efficacy, PK/PD, and combination strategy insights that enable candidate selection, IND-enabling studies, translational biomarker strategies, and clinical development decisions. The candidate will serve as a key scientific leader in disease area strategy discussions, helping prioritize indications, combination opportunities, biomarker hypotheses, and portfolio investments. Functional responsibilities include leadership, mentoring and development of a productive cancer pharmacology group, a facile translational research operations group, and AI/ML integration for modern data infrastructure and analytics. The leader is expected to work cross-functionally across a broad and growing R&D organization, including functions driving ADME, safety, regulatory affairs, and clinical development. We are seeking an experienced and visionary leader with strong interpersonal skills and an ability to lead a strong and diverse translational research team. The ideal candidate will:
Define and implement forward translation strategies for RAS-driven diseasessupervising an internal team of highly experienced and accomplished cancer pharmacologists to drive in vivo pharmacology in parallel with scientific discovery and combination strategies.
Drive efforts to organize and harmonize large data setsacross the organization, as part of a digital data transformation initiative, and accelerate integration and analysis of large scale preclinical and clinical datasets into our translational research strategy.
Champion the integration of advanced computational approaches, AI/ML methodologies, and modern data infrastructure to enable data-driven decision making across discovery, translational research, and development.
Be accountable for a sophisticated core operations groupthat can meet diverse needs across research, including international preclinical CRO management and internal regulatory and operational interactions.
Leverage strong cross-functional skillsto develop productive collaborations with diverse groups across the organization including research, development, and project teams.
Engage with external collaborations including academic centers, CROs, non-profit organizations and experts to drive execution of key projects and bring in new technologies.
Represent Revolution Medicines externally through scientific publications, conference presentations, advisory boards, and strategic collaborations.
Be a strategic leader and thought partner for disease area strategy initiativesto accelerate our pipeline, stay up to date with industry trends to identify future translational gaps and opportunities, develop plans to implement and help programs pivot to ensure future success.
Required Skills, Experience, and Education:
PhD in oncology, pharmacology, cancer biology, molecular biology, or related discipline, and background in the principles of oncology.
12+ years of experience in oncology drug discovery, ideally as a pharmacologist with expertise in PK/PD/efficacy for drug development in a life sciences environment.
Experience advancing small molecule oncology programs from discovery through IND and early clinical development.
Demonstrated success leading and developing high-performing scientific organizations and managing experienced scientific leaders.
Experience working at the interface between discovery and development within the oncology field is essential.
Strong strategic management/coordination skills, with the ability to develop project roadmaps, manage timelines, and align key stakeholders across departments.
Computational biology skills and/or experience with large data mining; familiarity with life science software platforms (e.g. Benchling), cloud-based storage, integration, and compute infrastructures.
Exceptional communication, collaboration, and leadership abilities, particularly in tackling complex projects involving diverse scientific, technical, and leadership teams.
Preferred Skills:
Project team leadership experience.
Experience coordinating the curation, ingestion, and harmonization of legacy scientific data across internal, external, public, and licensed data sources.
Ability to work in a high-energy, fast-paced, rapidly evolving and scaling company, operating in a highly competitive field.
#LI-Hybrid #LI-GL1
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Base Pay Salary Range 294000 - 367000 USD
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines